21 May 2025 - The pulmonary arterial hypertension medicine Adempas (riociguat) will be covered by national health insurance starting next month -- 11 years after its approval in Korea in 2014, Bayer Korea said.

According to a notice from the Ministry of Health and Welfare, Adempas will be covered for patients diagnosed with pulmonary arterial hypertension (WHO Group 1) in World Health Organization (WHO) functional classification stages 2 to 3, who have had an insufficient response to ERA (endothelin receptor blocker) and/or PDE-5 inhibitor pulmonary arterial hypertension drugs, or who are contraindicated for both ERA and PDE-5 inhibitor pulmonary arterial hypertension drugs.

Read Korea Biomedical Review article